Rubella
Also known as: German measles, Three day measles, Rubella syndrome, Disorder, Syndrome
Methodology & AI Transparency ⓘ
Rubella Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Rubella is an infection caused by a virus.
- 2 Real-world patient consensus: Mapped to Dermatology: Acne, Eczema, Psoriasis & Rosacea under ICD-10-CM P35.0 for Rubella clinical workups.
- 3 Typical cash cost range: Differential triage of Rubella (P35.0) utilizes or targeted biologics [Rubella P35.0].
- 4 Top reported side effects / signs: Follow-up benchmark in Rubella: maintaining Affected Body Surface in Rubella (P35.0: Area (BSA /) within Clear or Almost Clear (IGA 0–1) (P35.0).
Ask our AI Specialists anything about Rubella
What Is Rubella?
Rubella is an infection caused by a virus. It is usually mild with fever and a rash. About half of the people who get rubella do not have symptoms. If you do get them, symptoms may include: A rash that starts on the face and spreads to the body Mild fever Aching joints, especially in young women Swollen glands Rubella is most dangerous for a pregnant woman's baby. It can cause miscarriage or birth defects. Rubella spreads when an infected person coughs or sneezes. People without symptoms can still spread it. There is no treatment, but the measles-mumps-rubella (MMR) vaccine can prevent it. Centers for Disease Control and Prevention
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Rubella (P35.0) features epidermal barrier filaggrin/ceramide in Rubella (P35.0: disruption). Cross-referenced with NIH MeSH (Rubella), therapeutic stabilization in skin & dermatology is verified against Fasting Lipids & in Rubella (P35.0: ALT (if systemic).
Common Symptoms & Clinical Signs
- • A rash that starts on the face and spreads to the body
- • Aching joints, especially in young women
- • Presentation of Rubella (P35.0): post-inflammatory hyperpigmentation, facial in Rubella (P35.0: flushing, or pitted)
- • Secondary Rubella clinical sign: recurrent flares triggered in Rubella (P35.0: by UV exposure,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Rubella Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | P35.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Affected Body Surface in Rubella (P35.0: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (P35.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Fasting Lipids & in Rubella (P35.0: ALT (if systemic) | Within baseline reference limits (P35.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Rubella (P35.0: & hs-CRP) | 25(OH)D 40–65 ng/mL (P35.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Rubella
Treatment selection for Rubella depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Rubella)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Deucravacitinib in moderate-to-severe plaque psoriasis skin flare-ups: Pooled: What a 1,683-Participant Study Found Deucravacitinib was well-tolerated with acceptable safety over 52 weeks in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV • 2024-08-15 • Phase III Randomized Trial | N = 1,683 | 96/100 | PMID 38451052 ↗ |
| New Insights on Correlation of protection against varicella in a randomized Phase III: What a 5,803-Participant Study Found Varicella-specific antibody concentrations are a good predictor of protection, given their inverse correlation with varicella occurrence. Vaccine • 2021-06-08 • Phase III Randomized Trial | N = 5,803 | 90/100 | PMID 33736915 ↗ |
| Can This Approach Help? Inside the Latest Research on Sustained on/off-treatment disease control with abrocitinib for After 12 weeks of abrocitinib 200 mg, some patients achieved 40 weeks of sustained off-treatment disease control, with assessments demonstrating clear/mild AD, suggesting attainment of disease full symptom relief. The Journal of dermatological treatment • 2026-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42165315 ↗ |
| New Insights on Immunogenicity and safety of Mebella™ vaccine developed by Human Biologicals: What a 888-Participant Study Found It was concluded from the study results that the test vaccine, Mebella™, was immunogenic and well tolerated and was non-inferior to the comparator vaccine, MR-VAC®, when administered to healthy subjects of 9 months to 49 years... Vaccine • 2023-10-20 • Phase III Randomized Trial | N = 888 | 87/100 | PMID 37659893 ↗ |
| New Insights on Clinically- versus serologically-identified varicella: A hidden infection burden.: What a 744-Participant Study Found About one-third of children not vaccinated against varicella and not diagnosed with varicella developed an anti-VZV immune response, suggesting subclinical varicella occurrence. Human vaccines & immunotherapeutics • 2021-10-03 • Phase III Randomized Trial | N = 744 | 87/100 | PMID 34181506 ↗ |
Rubella Patient Community & “People Like Me” Threads
Filter Rubella community threads and patient logs by age, biological sex, dosage, and treatment duration.